First patient dosed inPhase 1/2 Clinical Trial of CDH17-directed...

First patient dosed in
Phase 1/2 Clinical Trial of CDH17-directed CAR-T cell therapy
• CHM CDH17 is a world leading CDH17-directed CAR-T cell therapy designed to treat
patients with gastrointestinal (GI) cancers
• The first-in-human clinical trial of CHM CDH17 is recruiting subjects at US Cancer
Centres with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine
tumours
• First patient dosed at Sarah Cannon Research Institute in Nashville, Tennessee
Sydney, Australia, 28 August 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the
“Company”), an Australian leader in cell therapy, is pleased to announce that the first patient
enrolled in the first-in-human trial of CHM CDH17 has been dosed.
The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended
Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with
advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.
“Treating our first patient is a key milestone for Chimeric as we work to advance new medicines
to improve the lives of patients living with cancer.” said Dr Rebecca McQualter, Chief Operating
Officer of Chimeric Therapeutics.
Paul Hopper, Executive Chairman, reflected on this milestone: “This is a great moment for
patients and the culmination of years of hard work by the Chimeric team.”
The phase 1 portion of this study is expected to enrol 15 patients and lead to dose selection and
expansion with indication-specific Phase 2 cohorts.
CHM CDH17 is a 3rd generation, novel CAR T cell therapy that targets CDH17, a cancer target
associated with poor prognosis and metastasis in the most common gastrointestinal tumours.
The clinical program for CHM CDH17 builds upon the preclinical studies published in the
preeminent scientific journal, Nature Cancer in March 2022 by leading immunotherapy scientist
Xianxin Hua, MD, PhD, and his team at the Abramson Family Cancer Research Institute at the
University of Pennsylvania. These experiments demonstrated that CHM CDH17 was able to
eradicate established tumours in seven cancer models with no toxicity to normal tissues.